Hindustan Laboratories Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Hindustan Laboratories Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of 1,41,00,000 Shares. The offering comprises a fresh issue component of 50,00,000 Shares.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Hindustan Laboratories Limited, incorporated in 2017, is a pharmaceutical company focused on manufacturing and supplying generic medicines mainly to government institutions under a B2G model. The company works closely with central and state government agencies, supplying medicines across all major states and union territories in India. Its product portfolio is wide, covering various therapeutic areas like anti-diabetic, anti-infective, cardiac, respiratory, and nutritional supplements, with nearly 950 products as of September 2025. It has capabilities across multiple dosage forms such as tablets, capsules, syrups, and creams, supported by its manufacturing facility in Palghar, Maharashtra, which meets quality standards, while an additional unit is being set up for future expansion. With a growing customer base and strong presence in government healthcare supply, the company continues to scale its operations supported by a workforce of over 600 people including contract staff.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Established Pharmaceutical Manufacturing: Engaged in production of medicines and healthcare products, ensuring consistent demand from hospitals and pharma companies.
- Wide Product Portfolio: Offers multiple formulations across therapeutic segments, reducing reliance on a single product line.
- Growing Healthcare Demand: Increasing need for pharmaceutical products supports long-term growth and scalability.
- Strict Regulatory Environment: Operations are subject to stringent compliance and quality standards, which can impact business if not maintained.
- Working Capital Intensive: Requires continuous investment in raw materials, production, and distribution, affecting cash flows.
- Competitive Industry: Faces strong competition from established pharma companies, leading to pricing pressure and margin challenges.
- Rajesh Vasantray Doshi
- Kunjal C Dedhia
- Krishiv Rajesh Doshi
Hindustan Laboratories Limited
Link Intime India Private Limited